Cargando…

Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East

Immunotherapy poses new considerations and alterations to the management of metastatic colorectal carcinoma (mCRC), where chemotherapy achieves complete radiological response but yields complete pathological response in few patients only. Immunotherapy may be superior in the conversion of unresectab...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakati, Rasha T, Faraj, Walid, Qaraqe, Taha, El Chaer, Frederic, Hussain, Hero, Shamseddine, Ali, Khalife, Mohamad Jawad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433095/
https://www.ncbi.nlm.nih.gov/pubmed/36059435
http://dx.doi.org/10.1093/jscr/rjac142
_version_ 1784780550927548416
author Kakati, Rasha T
Faraj, Walid
Qaraqe, Taha
El Chaer, Frederic
Hussain, Hero
Shamseddine, Ali
Khalife, Mohamad Jawad
author_facet Kakati, Rasha T
Faraj, Walid
Qaraqe, Taha
El Chaer, Frederic
Hussain, Hero
Shamseddine, Ali
Khalife, Mohamad Jawad
author_sort Kakati, Rasha T
collection PubMed
description Immunotherapy poses new considerations and alterations to the management of metastatic colorectal carcinoma (mCRC), where chemotherapy achieves complete radiological response but yields complete pathological response in few patients only. Immunotherapy may be superior in the conversion of unresectable disease to resectable liver lesions from mCRC and downsizing borderline lesions for more feasible resectability and achieving complete pathologic response, with the potential for cure and to alter current, established guidelines for surgical resection with a shift from chemotherapy. We present two patients with hepatic lesions from mCRC characterized by deficient mismatch repair (dMMR) which were unresectable after traditional chemotherapy but were converted to resectable lesions with a complete histopathological response following immunotherapy. Complete histopathologic response and radiologic regression or disappearance of liver lesions was observed in patients with dMMR mCRC after pembrolizumab. Immunotherapy exhibits notable potential for cure, achieving complete, successful surgical resection and improving prognosis.
format Online
Article
Text
id pubmed-9433095
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94330952022-09-01 Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East Kakati, Rasha T Faraj, Walid Qaraqe, Taha El Chaer, Frederic Hussain, Hero Shamseddine, Ali Khalife, Mohamad Jawad J Surg Case Rep Case Series Immunotherapy poses new considerations and alterations to the management of metastatic colorectal carcinoma (mCRC), where chemotherapy achieves complete radiological response but yields complete pathological response in few patients only. Immunotherapy may be superior in the conversion of unresectable disease to resectable liver lesions from mCRC and downsizing borderline lesions for more feasible resectability and achieving complete pathologic response, with the potential for cure and to alter current, established guidelines for surgical resection with a shift from chemotherapy. We present two patients with hepatic lesions from mCRC characterized by deficient mismatch repair (dMMR) which were unresectable after traditional chemotherapy but were converted to resectable lesions with a complete histopathological response following immunotherapy. Complete histopathologic response and radiologic regression or disappearance of liver lesions was observed in patients with dMMR mCRC after pembrolizumab. Immunotherapy exhibits notable potential for cure, achieving complete, successful surgical resection and improving prognosis. Oxford University Press 2022-08-31 /pmc/articles/PMC9433095/ /pubmed/36059435 http://dx.doi.org/10.1093/jscr/rjac142 Text en Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author(s) 2022. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Series
Kakati, Rasha T
Faraj, Walid
Qaraqe, Taha
El Chaer, Frederic
Hussain, Hero
Shamseddine, Ali
Khalife, Mohamad Jawad
Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title_full Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title_fullStr Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title_full_unstemmed Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title_short Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East
title_sort immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the middle east
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433095/
https://www.ncbi.nlm.nih.gov/pubmed/36059435
http://dx.doi.org/10.1093/jscr/rjac142
work_keys_str_mv AT kakatirashat immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT farajwalid immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT qaraqetaha immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT elchaerfrederic immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT hussainhero immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT shamseddineali immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast
AT khalifemohamadjawad immunotherapyformetastaticliverdiseasefromcolorectalcarcinomacaseseriesfromthemiddleeast